Oncology NEWS International Vol 19 No 2

Single-agent gefitinib doubles time-to-progression in non-small-cell lung cancer patients with EGF.

February 22, 2010

The seminal IPASS study by Tony Mok, MD, and colleagues demonstrated moderate efficacy for gefitinib (Iressa) in advanced non–small–cell lung cancer patients, most notably in patients with predictive factors, including adenocarcinoma histology, no history of smoking, and Asian ethnicity.

Renal Mass Biopsies May Help Patients Bypass Surgery

February 22, 2010

Using renal mass biopsy to guide treatment decisions for small tumors is cost-effective relative to direct surgery, and can spare many patients unnecessary surgical procedures, according to Massachusetts General Hospital researchers.

Re-treatment with gefitinib curbs disease progression

February 22, 2010

A second round of gefitinib (Iressa) slowed disease advancement in non-small-cell lung cancer patients who failed to respond to first-line treatment, according to a study presented at the 2010 Joint Conference on Molecular Origins in Lung Cancer.

High-dose fulvestrant improves outlook in advanced ca

February 22, 2010

Higher doses of the estrogen-receptor antagonist fulvestrant (Faslodex) may increase treatment benefit without increasing toxicity, according to results from the international, randomized, double-blind phase III CONFIRM trial.

Who's News

February 12, 2010

ASCO and RSNA elect new presidents while the Children's Oncology Group selects a new leader. Read more about the latest awards and appointments in oncology and cancer care.